The Journal of Pediatrics
Volume 149, Issue 6 , Pages 740-742 , December 2006

Midodrine for the treatment of vasovagal syncope (simple FAINT)

  • Julian M. Stewart, MD, PhD

      Affiliations

    • Corresponding Author InformationReprint requests: Julian M. Stewart MD, PhD, Professor of Pediatrics and Physiology, Research Division and Hypotension Laboratory, New York Medical College, Suite 3050, 19 Bradhurst Avenue, Hawthorne, NY 10532

References 

  1. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34:D668–D672
  2. Stewart JM, Munoz J, Weldon A. Clinical and physiological effects of an acute alpha-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance. Circulation. 2002;106:2946–2954
  3. Corr PB, Heathers GP, Yamada KA. Mechanisms contributing to the arrhythmogenic influences of alpha 1-adrenergic stimulation in the ischemic heart. Am J Med. 1989;87:19S–25S
  4. Vatner SF. Regulation of coronary resistance vessels and large coronary arteries. Am J Cardiol. 1985;56:16E–22E
  5. Gilden JL. Midodrine in neurogenic orthostatic hypotension: a new treatment. Int Angiol. 1993;12:125–131
  6. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study (Midodrine Study Group). JAMA. 1997;277:1046–1051
  7. McClellan KJ, Wiseman LR, Wilde MI. Midodrine: a review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging. 1998;12:76–86
  8. Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology. 1996;46:1470
  9. Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95:38–48
  10. Piwinski SE, Jankovic J, McElligott MA. A comparison of post–space flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. J Clin Pharmacol. 1994;34:466–471
  11. Ramsdell CD, Mullen TJ, Sundby GH, Rostoft S, Sheynberg N, Aljuri N, et al. Midodrine prevents orthostatic intolerance associated with simulated space flight. J Appl Physiol. 2001;90:2245–2248
  12. Mitro P, Trejbal D, Rybar AR. Midodrine hydrochloride in the treatment of vasovagal syncope. Pacing Clin Electrophysiol. 1999;22:1620–1624
  13. Perez-Lugones A, Schweikert R, Pavia S, Sra J, Akhtar M, Jaeger F, et al. Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study. J Cardiovasc Electrophysiol. 2001;12:935–938
  14. Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: a role in the management of neurocardiogenic syncope. Heart. 1998;79:45–49
  15. Kaufmann H, Saadia D, Voustianiouk A. Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study. Ann Neurol. 2002;52:342–345
  16. Qingyou Z, Junbao D, Chaoshu T. The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope. J Pediatr. 2006;149:777
  17. Strickberger SA, Benson DW, Biaggioni I, Callans DJ, Cohen MI, Ellenbogen KA, et al. AHA/ACCF Scientific Statement on the evaluation of syncope from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke and the Quality of Care and Outcomes Research Interdisciplinary Working Group and the American College of Cardiology Foundation, in collaboration with the Heart Rhythm Society; endorsed by the American Autonomic Society. Circulation. 2006;113:316–327
  18. Berkowitz JB, Auld D, Hulse JE, Campbell RM. Tilt table evaluation for control pediatric patients: comparison with symptomatic patients. Clin Cardiol. 1995;18:521–525
  19. Petersen ME, Williams TR, Gordon C, Chamberlain-Webber R, Sutton R. The normal response to prolonged passive head-up tilt testing. Heart. 2000;84:509–514
  20. Sheldon R, Connolly S, Rose S, Klingenheben T, Krahn A, Morillo C, et al. Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. Circulation. 2006;113:1164–1170
  21. Miller FG, Rosenstein DL. The nature and power of the placebo effect. J Clin Epidemiol. 2006;59:331–335
  22. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287:622–627

PII: S0022-3476(06)00785-2

doi: 10.1016/j.jpeds.2006.08.026

The Journal of Pediatrics
Volume 149, Issue 6 , Pages 740-742 , December 2006

Article Tools